This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Generex Biotechnology Valuation

Is GNBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GNBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GNBT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GNBT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GNBT?

Key metric: As GNBT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GNBT. This is calculated by dividing GNBT's market cap by their current revenue.
What is GNBT's PS Ratio?
PS Ratio	0.09x
Sales	US$692.76k
Market Cap	US$61.03k

GNBT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	30.7x
Enterprise Value/EBITDA	-0.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GNBT's PS Ratio compare to its peers?

Insufficient data to calculate this valuation analysis check

The above table shows the PS ratio for GNBT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	n/a
GNBT Generex Biotechnology	0.09x	n/a	US$61.0k

Price-To-Sales vs Peers: Insufficient data to calculate GNBT's Price-To-Sales Ratio vs. peers for valuation analysis.

Price to Sales Ratio vs Industry

How does GNBT's PS Ratio compare vs other companies in the US Biotechs Industry?

124 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	10.0x	21.7%
GNBT Generex Biotechnology	0.09x	n/a	US$61.03k
BIIB Biogen	2.4x	1.3%	US$23.29b
MRNA Moderna	3.3x	6.7%	US$16.70b

124 Companies		Estimated Growth	Market Cap
Industry Avg.	10.0x	28.5%
GNBT Generex Biotechnology	0.09x	n/a	US$61.03k

No more companies

Price-To-Sales vs Industry: GNBT is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Biotechs industry average (13x)

Price to Sales Ratio vs Fair Ratio

What is GNBT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNBT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.09x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GNBT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

8.2%

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

2.5%

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

-0.2%

-7.1%